Vitamin D Levels in Patients with Premature Ovarian Failure

Pełen tekst

(1)P R A C E O R Y G I N A L N E ginekolog i a. DOI: 10.17772/gp/57839. Ginekol Pol. 2016, 87, 32-36. Vitamin D levels in patients with premature ovarian failure Poziom witaminy D u pacjentek z przedwczesnym wygasaniem czynności jajników

(2)

(3)

(4)

(5) Zekai Tahir Burak Women’s Health Care, Training and Research Hospital, Ankara, Turkey. Abstract Objective: To investigate the role of vitamin D in the pathogenesis of premature ovarian failure. Method: Forty-eight women diagnosed with POF, and 82 women recruited as controls were included in this crosssectional study, between January 2014 and April 2014, in a reference center of infertility in the capital of Turkey. 25(OH)D3 levels of the patients were determined with the use of a specific enzyme-linked immunosorbent assay kit. Results: There was no difference between two groups in terms of age, body mass index, smoking status, or sunlight exposure. 25(OH)D3 levels did not differ between the POF group (7.75 [3-21.22] μg/L) and the control group (6.74 [3-25.54] μg/L) (P = 0.477). There was no significant correlation between vitamin D and follicle stimulating hormone levels or between vitamin D and estradiol levels. Conclusion: Although vitamin D level was reported to play a role in ovarian physiology, it seems not to have a role in the etiology of POF. Larger nation-wide or world-wide studies should be carried out to clarify the exact mechanism of POF.. Key words:

(6) / etiology / ovarian reserve / / premature ovarian failure /. Autor do korespondencji: Ebru Ersoy Zekai Tahir Burak Women’s Health Care, Training and Research Hospital, Talatpasa Bulv. Hamamonu, 06230, Altindag, Ankara, Turkey e-mail: eebruersoy09@gmail.com. 32. © Polskie Towarzystwo Ginekologiczne. Otrzymano: 03.02.2015 Zaakceptowano do druku: 08.02.2015. Nr 1/2016.

(7) Ginekol Pol. 2016, 87, 32-36. DOI: 10.17772/gp/57839. P R A C E. O R Y G I N A L N E g i n e kol og i a. Ebru Ersoy et al. Vitamin D levels in patients with premature ovarian failure.. Streszczenie Cel pracy: Ocena roli witaminy D w patogenezie przedwczesnego wygasania czynności jajników. Metoda: Do badania przekrojowego włączono 48 kobiet ze zdiagnozowanym POF i 82 kobiety jako grupa kontrolna, w okresie pomiędzy styczniem 2014 a kwietniem 2014, w ośrodku referencyjnym leczenia niepłodności w stolicy Turcji. Poziom 25(OH)D3 u pacjentek oznaczono przy użyciu specyficznego powiązanego z enzymem immunoabsorpcyjnego zestawu testowego. Wyniki: nie znaleziono różnic pomiędzy grupami dotyczących wieku, BMI, palenia tytoniu i ekspozycji na promieniowanie słoneczne. Poziom 25(OH)D3 nie różnił się pomiędzy grupą z POF (7.75 [3-21.22] μg/L) a grupą kontrolną (6.74 [3-25.54] μg/L) (P = 0.477). Nie było istotnych związków pomiędzy witaminą D a poziomem hormonów stymulujących jajeczkowanie oraz pomiędzy poziomem witaminy D a poziomem estradiolu. Wnioski: chociaż mówi się, że witamina D pełni istotna rolę w fizjologii jajnika, to wydaje się że nie ma znaczenia w powstawaniu POF. Dalsze szerzej zakrojone badania krajowe i światowe są potrzebne aby wyjaśnić dokładny mechanizm POF.. Słowa kluczowe: niedobór witaminy D / etiologia / rezerwa jajnikowa / / /. Introduction. Materials and Method. ! "

(8) # $%

(9)

(10) & & ' & & " & "

(11)

(12)

(13) " &"() "

(14) "! &

(15) " *+ ,-. '& " () /-0* & " & 1! ( & & 11 #$

(16)

(17)

(18)

(19) &2 $34 5 () +67% & 1 /80 9

(20)

(21) '

(22) !

(23) " :;<

(24)

(25) & # ;4% #

(26) ' &

(27) !

(28) " )*)8 =67% & 1 1

(29) " " $ />0* $

(30)

(31) " 1 1

(32) " & 1

(33) " 1

(34) "

(35)

(36)

(37) & ! * @

(38) " " "

(39) ' & &

(40)

(41) 1 " $ & "A

(42) "

(43) # ** ! %*4

(44)

(45)

(46)

(47) !

(48) 1

(49) '

(50)

(51)

(52) 1 *

(53) && 9 1 " &! 1

(54) &

(55) " $ 9

(56)

(57) /(:B0* &" $

(58) "

(59) & * C D

(60) & & ' & & 1 "

(61) !

(62) #C%

(63) & #1

(64)

(65) C:%* + ! ! " " - 8E & 9 :! D> & 8E:& 9

(66) -F:& 9

(67)

(68) &

(69) ! 1 !

(70) *-F:& 9

(71)

(72) 1 & ! 12 - 8E & 9 :! D>

(73) &

(74)

(75)

(76) &*C D""

(77) &

(78)

(79)

(80)

(81)

(82) 1

(83) 11 " *C D9 ""! 1#C D1/CD@0% &

(84)

(85) *CD@ " & ! & 11& & 1&

(86) /G H0* +

(87)

(88) & 11

(89)

(90) "! D &"

(91) 1 ! /I0*C D

(92) 1&!""& "& ;<

(93)

(94) 4# ;4%"&

(95)

(96)

(97) &! /-)0* '

(98) ' ;4&

(99) !

(100) "$34 ! ": & * + & 9 ' ! &1

(101)

(102) "! D &

(103) " $*. ' :

(104) & J & KL4

(105) &M @& 41

(106) '& & "

(107)

(108) '& "N 8)-( 1

(109) 8)-(*&

(110) ! ' 11! & !

(111) 1 1

(112) " & 4

(113) D

(114) # ! 8)))% ' 11

(115) * ' 1'

(116) &2"&

(117) M ' ' & $ # O (H% & & 1

(118) M '

(119) #OH8%*

(120)

(121) "&1 ' 1&

(122) 9 " 9& ' & ! "

(123) #** ' & 1

(124) $

(125) P %*& " $ ' " $34 5 () 67 # ' & A

(126)

(127) % &"

(128) 9& 1

(129) '&"()*

(130) 1 '

(131) '&"()' &

(132)

(133) &! &

(134) ' &

(135) ' & & " "

(136) *K'9

(137) "&"

(138)

(139) ' Q " "

(140)

(141) & " & #**

(142) !

(143) &

(144)

(145) % & " ! &&1 &1 " ! 6

(146)

(147) ""&

(148) !

(149) "! D ! ! #** &

(150)

(151) &

(152) %* & " 8E#4%D> 1 & " ! D

(153) !

(154) R ! D

(155) !

(156) "& : & *8E#4% D>

(157) !

(158) &&&&

(159)

(160) /--0* & 8E#4%D>'! D

(161) !

(162) *& 1 '

(163) ' & &' '& & :

(164) &

(165) !

(166) '

(167) !

(168)

(169) ' & " #7 Q()S()v 7 Q>8S>(v

(170) QHI- & !1 )*(T--*>SM%/-80*D

(171)

(172)

(173) &

(174)

(175) ' &

(176) ' ' & * @ "

(177)

(178)

(179) &1 *&'&' ",E ' ",E "&& & 1 *+ ' ",(&1 & 1 *

(180)

(181) "& 1 &! 91 :

(182) & " . Nr 1/2016. © Polskie Towarzystwo Ginekologiczne. 33.

(183) P R A C E O R Y G I N A L N E ginekolog i a. Ginekol Pol. 2016, 87, 32-36. DOI: 10.17772/gp/57839. Ebru Ersoy et al. Vitamin D levels in patients with premature ovarian failure.. Tabl e I . Comparison of demographic characteristics of the patients. Characteristic Age (years). n = 48). Control group (n = 82). P value. 33.3±5.2. 32.4±3.9. 0.293. 34 (70.8%). 50 (61%). 0.342. Gravidity. 0 (0 – 4). 2 (0 – 6). <0.001*. Parity. 0 (0 – 3). 2 (0 – 5). <0.001*. Abortus. 0 (0 – 1). 0 (0 – 2). <0.001*. Live Born. 0 (0 – 3). 2 (0 – 5). <0.001*. 25.7±3.9. 24.7±3.9. 0.155. 14 (29.2%). 21 (25.6%). 0.813. Age > 30 years [n(%)]. 2. BMI (kg/m ) Smoking. Values were given as mean±standard deviation or median (range) or number (percentage). *Statistically significant; POF: Premature ovarian failure; BMI: Body mass index. Tabl e I I . Comparison of basal hormone and 25(OH)D3 levels between two groups. Characteristic. n = 48). Control group (n = 82). P value. FSH (mIU/mL). 60.5 (40 – 149). 6 (2.42 – 10.0). <0.001*. LH (mIU/mL). 32 (12 – 61). 4 (1 – 10). <0.001*. Estradiol (pg/mL). 14 (5 – 29). 43 (19 – 93.63). <0.001*. Prolactin (μg/L). 9.62±4.42. 11.11±4.62. 0.074. TSH (mIU/L) 25(OH)D3 (ng/mL). 1.87±0.80. 2.00±0.91. 0.406. 7.75 (3 – 21.22). 6.74 (3 – 25.54). 0.477. Values were given as mean±standard deviation or median (range). *Statistically significant; POF: Premature ovarian failure; FSH: Follicle stimulating hormone; LH: Luteinizing hormone; TSH: Thyroid stimulating hormone.. ">) 1 *C

(184) & '

(185) 1

(186) "

(187) '& ' *'1'&"

(188) "

(189) 1&1& ! D *

(190)

(191) ' & ! ' " 1 1* $

(192)

(193) ' -) & " "

(194) 1

(195) ' " &

(196) !

(197) & "&

(198)

(199) &:1"# 91

(200) &%*31

(201) '1 " E ))) 1 #8 8>B % " -) ' & -ET8) "

(202) 1

(203)

(204) " " * & 8E#4%C D>

(205) !

(206) ' 7+3 #+ 7! %*

(207)

(208)

(209) 1

(210) '

(211) & &

(212) " &1

(213) * & : : " " ! ' H*I -)*B. " 8E#4%C D>*

(214)

(215) !

(216) " $34 #' & & " +

(217) 8)))

(218) @6D M7 ' U2 : ! "(*). : ! "B*G.%74#+

(219) 8)))

(220) 2 : ! " (*H. : ! " -)*G.%

(221) #' &&"+

(222) 8)))

(223) 2 : ! "B*G. : ! "I*G.% 1

(224) &

(225) & #34% '

(226)

(227) &! * &1 '

(228)

(229) & "

(230) 1

(231) *4 &' &"&1 ' 1"

(232)

(233)

(234) ! * 9#;+%'

(235)

(236) ' &

(237) ! & & A# ** 68%*. 34. D'

(238) ' &&"&+;: 3 33"K 'C 8-*)#+;:3 33 3 % 1*& "&!

(239) ' & U

(240) !:3 ! 3&1 :K

(241) * M !

(242) '1&! #3D% #%

(243) !

(244) 1& 1 " V* M !

(245) ' 1 1:1

(246) t: "& '

(247)

(248) ' &&;TK& U "& ':

(249)

(250) * M

(251) !

(252) '

(253) & W8 $ &L 9 * 31L

(254) " '

(255)

(256) " :

(257)

(258) !

(259) * +

(260)

(261)

(262) ':

(263) P:!

(264) " X )*)E'

(265)

(266) *. Results :&:& 1 '&"88>I ' "& *"& (H1 #>B*I.%' & $1 H8#B>*-.%' &

(267) 1*& "&1 & $1'>>*>YE*8 >8*(Y>*I &

(268) 1#

(269) +%*&' ""'&'1 "#PO)*8I>%* &"1 !&">)'>(#G)*H.% & $1 E)#B-.% &

(270) 12&'1 '

(271) " & !

(272) #P O )*>(8%* & & '

(273) ""'1#

(274) +%*&' ""'&'1 ";+ #PO)*-EEPO)*H-> 1 !

(275) %#

(276) +%*. © Polskie Towarzystwo Ginekologiczne. Nr 1/2016.

(277) Ginekol Pol. 2016, 87, 32-36. DOI: 10.17772/gp/57839. P R A C E. O R Y G I N A L N E g i n e kol og i a. Ebru Ersoy et al. Vitamin D levels in patients with premature ovarian failure.. Figure 1. The concentration of 25(OH)D3 and its changing levels in sera of the patients diagnosed with POF and controls. The 95% confidence interval was used.. $34

(278) !

(279) & $ 1 #B)*E 67 " () -(I67%'

(280) & && &

(281) 1 #B67 "8*(8-)*)%#PX)*))-%*&74

(282) !

(283) & $ 1 #>8 67 " -8 B- 67% '

(284) & &&&

(285) 1#B67 " 8*(8-)*)67%#PX)*))-%*

(286)

(287) !

(288) & $1 #-(167 "E8I167%'

(289)

(290) ' &&

(291) 1#(>167 "-II>*B>16 7%#PX)*))-%*

(292) 34

(293) !

(294) '

(295) ' &'1#PO)*)G(2PO)*()B 1 !

(296) %#

(297) ++%* & E#4%D>

(298) !

(299) "" ' & $ #G*GE Z67 " > 8-*88 Z67%

(300) #B*G( Z67 ">8E*E(Z67%1#PO)*(GG%#

(301) 8 $ -%* &'

(302) '&8E#4%D> $34

(303) !

(304) "

(305)

(306) ->) 1 #r O )*)G)2 P O )*(8%*

(307) &'

(308) '&8E#4%D>

(309)

(310) !

(311) "

(312)

(313) ->)1 #rOT)*)HB2PO)*>>-%*. Discussion $

(314) "11 "! "

(315)

(316)

(317) &&&! 1&

(318) /->0*C

(319)

(320) &! 1& * ; "&$;@-/-(01

(321) 1& "&3$- /-E0 & :

(322) 1&#+4 %91

(323) "

(324) /-B0* $& 1

(325) & &&

(326)

(327)

(328) &

(329) &28 8: #&

(330) %:- >: 11

(331) 2 /01 2 &

(332) /-G0 /-H0'&'

(333) $* &

(334) " & 3 ! D X 8) 67 " ' 8) >) 67 /-I0* + ' '&91 & & && &

(335) !

(336) " ! D #G(*I.% ' /8)0* + N

(337) * &M

(338) #3 % 1

(339) "! D #GE.%/8-0* K& 1

(340) & ' 1

(341) & ! D '& & &

(342)

(343)

(344) 1

(345)

(346) &. Nr 1/2016. 1& " $* !&

(347) ' " "" ' $

(348) 1 " ! D

(349) !

(350) * + + ;& ' " & ! D &

(351)

(352) ! 1&

(353) /880*;! ! &&!

(354) &'&! D &

(355) !

(356) " ;4/8- 8>0* C D'" ' &! ! an in vitro 9 ""

(357)

(358)

(359) ! & 91 "&1" ;4:8# ;4@:8%$34 #$34@%/8-0 '&

(360) & 11 !

(361) ' ;4! D

(362) !

(363) /-)0*4'! & ' & '

(364) '&&

(365)

(366)

(367) '1 ! 1

(368)

(369)

(370) "

(371)

(372)

(373) * C D & & " ;4

(374)

(375)

(376) ;4$34

(377) !

(378) !": & " $34 & *+& 9 '& 1& &! D & ;4

(379) !

(380)

(381)

(382) ! $34

(383) !

(384) A

(385) $* !&

(386) ' " "" &! D

(387) !

(388) '"& $

(389) 1

(390) ' & ! D$34

(391) !

(392) *& 11

(393) "! D &1& " $*4'! N

(394) * " & &

(395) ! ' 8E#4% D$34

(396) !

(397) ' &-)67 8E#4%D ' &

(398) -). $34 /8(0* 7 ' & & " & 3 8E#4%D

(399) !

(400) ' !

(401)

(402) ' &$34

(403) !

(404) /8E0* &1

(405) 11

(406)

(407) '" '

(408) " * &" & " ' &

(409) 1

(410) " "" 1& '& &! "" :

(411) & 91* &

(412) '&" ;4

(413) !

(414) * +"& ;4

(415) !

(416) '!

(417)

(418) ' &$34 ! D

(419) !

(420) &

(421) *. Conclusion

(422) && ! D

(423) !

(424) ' 1 1

(425)

(426) ! 1&

(427) &!

(428) &

(429) " $*& "& "&1!

(430)

(431) "&1 " $ '& &

(432)

(433) :' '

(434) :' *. Acknowledgments.

(435)

(436)

(437) th ! "#$%&'()*"th–9th +%&, & . Authors’ contribution: 1. Ebru Ersoy – study design interpretation of data, article draft corresponding author. 2. Ali Ozgur Ersoy – acquisition of data, analysis, revised article critically. 3. Gulcin Yildirim – study design, acquisition of data, arcticle draft. 4. Umran Buyukkagnıcı – concept, interpretation of data, analysis, revised article critically. 5. Aytekin Tokmak – interpretation of data, analysis, revised article critically. 6. Nafiye Yılmaz – study design, interpretation of data, revised article critically.. © Polskie Towarzystwo Ginekologiczne. 35.

(438) P R A C E O R Y G I N A L N E ginekolog i a. DOI: 10.17772/gp/57839. Ginekol Pol. 2016, 87, 32-36. Ebru Ersoy et al. Vitamin D levels in patients with premature ovarian failure.. Authors’ statement ³ >RS] S] ^Y MO\^SPc ^RK^ ^RO Z_LVSMK^SYX aSVV XY^ `SYVKÔ ^RO MYZc\SQR^] YP K. third party, as understood according to the Act in the matter of copyright and related rights of 14 February 1994, Official Journal 2006, No. 90, Clause 63, with respect to the text, data, tables and illustrations (graphs, figures, photographs); ³ ^RO\O S] XY mMYX»SM^ YP SXÔ\O]^]p aRSMR YMM_\] aROX ^RO K_^RY\ \OWKSX] SX. a financial or personal relationship which unjustly affects his/her actions associated with the publication of the manuscript; ³ KXc ZY]]SLVO \OVK^SYX]RSZ] YP ^RO K_^RY\] aS^R ^RO ZK\^cZK\^SO]. interested in the publication of the manuscript are revealed in the text of the article; ³ ^RO WKX_]M\SZ^ RK] XY^ LOOX Z_LVS]RON SX Y\ ]_LWS^ÔN ^Y KXc Y^RO\. journal. ³ =Y_\MO YP ºXKXMSXQ$ 8YXO. K O M U N I K A T. Re fe re nc e s 1. Vujovic S, Brincat M, Erel T, [et al.]. EMAS position statement: managing women with premature ovarian failure. Maturitas. 2010, 67, 91–93. 2. Goswami D, Conway GS. Premature ovarian failure. Horm Res. 2007, 68, 196-202. 3. Knauff EA, Eijkemans MJ, Lambalk CB, [et al.]. Anti-Mullerian hormone, inhibin B, and antral follicle count in young women with ovarian failure. J Clin Endocrinol Metab. 2009, 94, 786–792. 4. Goswami D, Conway GS. Premature ovarian failure. Hum Reprod Update. 2005, 11, 391–410. 5. Yan G, Schoenfeld D, Penney C, [et al.]. Identification of premature ovarian failure patients with underlying autoimmunity. J Women’s Health Gender-Based Med. 2000, 9, 275–287. 6. Beck-Peccoz P, Persani L. Premature ovarian failure. Orphanet J Rare Dis. 2006, 1, 9. 7. Hurley WL, Doane RM. Recent developments in the roles of vitamins and minerals in reproduction. J Dairy Sci. 1989, 72, 784–804. 8. Kinuta K, Tanaka H, Moriwake T, [et al.]. Vitamin D is an important factor in estrogen biosynthesis of both female and male gonads. Endocrinol. 2000, 141, 1317–1324. 9. Anagnostis P, Karras S, Goulis DG. Vitamin D in human reproduction: a narrative review. Int J Clin Pract. 2013, 67, 225–235. 10. Dennis NA, Houghton LA, Jones GT, [et al.]. The level of serum anti-mullerian hormone correlates with vitamin D status in men and women but not in boys. J Clin Endocrinol Metab. 2012, 97, 2450–2455. 11. Johnson LE, DeLuca HF. Vitamin D receptor null mutant mice fed high levels of calcium are fertile. J Nutr. 2001, 131, 1787–1791. 12. Turkish State Meteorological Service. www.mgm.gov.tr. Official statistics of Ankara. Available from: www.mgm.gov.tr/veridegerlendirme/il-ve-ilceler-istatistik.aspx?m¼ANKARA#sfB [last accessed 31 Dec 2014]. 13. Vujovic S. Aetiology of premature ovarian failure. Menopause Int. 2009, 15, 72-75. 14. Gleicher N, Weghofer A, Oktay K, Barad D. Relevance of triple CGG repeats in the FMR1 gene to ovarian reserve. Reprod Biomed Online. 2009, 19, 385-390. 15. Jeyasuria P, Ikeda Y, Jamin SP, [et al.]. Cell-specific knockout of steroidog¬enic factor 1 reveals its essential roles in gonadal function. Mol Endocrinol. 2004, 18, 1610-1619. 16. Chand AL, Harrison CA, Shelling AN. Inhibin and prema¬ture prema¬ture ovarian failure. Hum Reprod Update. 2010, 16, 39-50. 17. Béranger R, Hoffmann P, Christin-Maitre S, Bonneterre V. Occupational exposures to chemicals as a possible etiology in premature ovarian failure: a critical analysis of the literature. Reprod Toxicol. 2012, 33, 269-279. 18. Chang SH, Kim CS, Lee KS, [et al.]. Premenopausal factors influencing premature ovarian failure and early menopause. Maturitas. 2007, 58, 19-30. 19.. Holick MF, Binkley NC, Bischoff-Ferrari HA, [et al.]. Evaluation, treatment, and prevention of vitamin D deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011, 96, 1911–1930.. 20. Hekimsoy Z, Dinç G, Kafesçiler S, [et al.]. Vitamin D status among adults in the Aegean region of Turkey. BMC Public Health. 2010, 10, 782. 21. Merhi Z, Doswell AD, Krebs K, Cipolla MJ. Vitamin D alters genes involved in follicular development and steroidogenesis in human cumulus granulosa cells. J Clin Endocrinol Metab. 2014, 99, E1137-1145. 22. Irani M, Merhi Z. Role of vitamin D in ovarian physiology and its implication in reproduction: a systematic review. Fertil Steril. 2014, 102, 460-468. 23. Merhi ZO, Seifer DB, Weedon J, [et al.]. Circulating vitamin D correlates with serum antimüllerian hormone levels in late-reproductive-aged women: Women’s Interagency HIV Study. Fertil Steril. 2012, 98, 228-234. 24. Jukic AM, Steiner AZ, Baird DD. Association between serum 25-hydroxyvitamin D and ovarian reserve in premenopausal women. Menopause. 2015, 22, pp. 25. Kebapcilar AG, Kulaksizoglu M, Kebapcilar L, [et al.]. Is there a link between premature ovarian failure and serum concentrations of vitamin D, zinc, and copper? Menopause. 2013, 20, 94-99.. 36. © Polskie Towarzystwo Ginekologiczne. Nr 1/2016.

(439)